Verapamil temperature-sensitive sustained-release preparation and preparation method and application thereof

Abstract

The invention provides a verapamil temperature-sensitive sustained-release preparation. The verapamil temperature-sensitive sustained-release preparation comprises drug-loaded denatured albumin, a multi-chamber liposome (SUV) and a temperature-sensitive adhesive, wherein the drug-loaded denatured albumin comprises denatured albumin and an effective amount of verapamil. The invention also providesa preparation method and application of the verapamil temperature-sensitive sustained-release preparation. According to the preparation, human serum albumin is denatured and then incubated with verapamil to adsorb verapamil to form drug nanoparticles, albumin-verapamil drug nanoparticles are wrapped with small single-chamber lipidosome, and finally the drug nanoparticles are mixed with a temperature-sensitive preparation poloxamer 127 to form a drug-loaded albumin nanoparticle-multi-chamber lipidosome-temperature-sensitive adhesive three-phase slow release system.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a temperature-sensitive sustained-release preparation of verapamil and its preparation method and application. Background technique [0002] Hepatocellular Carcinoma (HCC) is the most important pathological type of liver tumors. Most HCC patients are diagnosed at the advanced stage when they are first diagnosed, and they lose the chance of radical treatment such as liver transplantation or surgery. The median survival time is Only 3-6 months. HCC is characterized by multidrug resistance (Multi-Drug Resistance, MDR) to cytotoxic antitumor drugs, which makes HCC patients insensitive to cytotoxic chemotherapy drugs. At present, Sorafenib, the only first-line treatment drug for patients with advanced HCC, is an oral molecular targeted drug (i.e. multi-target small molecule protein kinase inhibitor): ① On the one hand, it can block vascular endothelial growth factor Vas...

AI Technical Summary

Problems solved by technology

Although verapamil may enter clinical trials as a chemosensitizer, there are still many problems to be solved: (1) verapamil itself was first used as an L-type calcium channel (L-type calcium channels, LTCs) Antagonists are widely used in clinical diagnosis and treatment, and can be used to treat arrhythmia and pain. For example, as an anti-tumor adjuvant drug, Verapamil will be distributed systemically regardless of oral or intravenous infusion, and it will affect the cardiovascular, nervous and muscular systems. (2) MDR-1 also has its own important physiological functions and is the basis of active material transport (ATP-dependent material transport)

Images